These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19947355)

  • 1. Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking.
    Das AM; Naim HY
    Adv Clin Chem; 2009; 49():57-71. PubMed ID: 19947355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastroenterological complications of Anderson-Fabry disease.
    Buda P; Książyk J; Tylki-Szymanska A
    Curr Pharm Des; 2013; 19(33):6009-13. PubMed ID: 23448457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anderson-Fabry disease: developments in diagnosis and treatment.
    Mehta AB
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S66-74. PubMed ID: 20040315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous complications of Anderson-Fabry disease.
    Giuseppe P; Daniele R; Rita BM
    Curr Pharm Des; 2013; 19(33):6031-6. PubMed ID: 23448454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
    Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
    G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
    Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
    Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases.
    Ivanova MM; Changsila E; Iaonou C; Goker-Alpan O
    PLoS One; 2019; 14(1):e0210617. PubMed ID: 30633777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.
    Desnick RJ; Brady R; Barranger J; Collins AJ; Germain DP; Goldman M; Grabowski G; Packman S; Wilcox WR
    Ann Intern Med; 2003 Feb; 138(4):338-46. PubMed ID: 12585833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fabry disease: treatment and diagnosis.
    Rozenfeld PA
    IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A.
    Machann W; Breunig F; Weidemann F; Sandstede J; Hahn D; Köstler H; Neubauer S; Wanner C; Beer M
    Eur J Heart Fail; 2011 Mar; 13(3):278-83. PubMed ID: 21149315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
    Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
    Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early therapeutic intervention in females with Fabry disease?
    Hughes DA
    Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fabry disease and cardiovascular involvement.
    Anastasakis A; Papatheodorou E; Steriotis AK
    Curr Pharm Des; 2013; 19(33):5997-6008. PubMed ID: 23448453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anderson Fabry disease: a multiorgan metabolic disease susceptible of treatment.
    Tuttolomondo A
    Curr Pharm Des; 2013; 19(33):5972-3. PubMed ID: 23448458
    [No Abstract]   [Full Text] [Related]  

  • 17. [Management of Fabry disease].
    Constantin T; Székely A; Ponyi A; Gulácsy V; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Medvecz M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Rákóczi E; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G
    Orv Hetil; 2010 Aug; 151(31):1243-51. PubMed ID: 20656661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fabry disease.
    Schiffmann R
    Pharmacol Ther; 2009 Apr; 122(1):65-77. PubMed ID: 19318041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fabry Disease: Pathogenesis, Clinical Symptoms, and Treatment with Enzyme Replacement Therapy].
    Sawai S
    Brain Nerve; 2015 Sep; 67(9):1099-108. PubMed ID: 26329150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fabry disease].
    Subran B; Montagner C; London J; Lidove O; Mauhin W
    Rev Prat; 2020 May; 70(5):537-540. PubMed ID: 33058644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.